Revenue segments as reported by the company.

Smokeable Products

Oral Tobacco Products

Wine

All Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, administration and research costs

Asset impairment and exit costs

Amortization of intangibles

General corporate expenses

Corporate asset impairment and exit costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Altria

Altria Group, Inc. operates as a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral tobacco products, and Wine. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral tobacco products segment is primarily moist smokeless tobacco products (MSTs) through brands like Copenhagen and Skoal as well as on! oral nicotine pouches sold by Helix. The Wine segment, through subsidiary Ste. Michelle Wine Estates Ltd, produces Washington State wines, primarily Chateau Ste. Michelle and 14 Hands, and owns wineries in or distributes wines from several other wine regions. The company was founded in 1919 and is headquartered in Richmond, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altria reports robust Q4 earnings, focuses on innovation and growth

Altria's Q4 2022 performance reflects resilience amidst industry challenges, with a focus on innovation and shareholder returns. The company's strategic initiatives in smoke-free products and digital engagement underscore its commitment to long-term growth and harm reduction.

Altria reports resilient Q1 performance amid industry challenges and opportunities

Altria's Q1 2023 earnings call highlighted strong performance amidst industry challenges, emphasizing harm reduction and regulatory compliance. The company faces hurdles from inflation, regulatory changes, and evolving consumer behaviors, while focusing on growth opportunities in smoke-free products and strategic investments.

Altria reports solid Q2 earnings, eyes e-vapor growth opportunities

Altria's focus on smoke-free products and NJOY acquisition driving growth.
Challenges in the cigarette industry due to economic pressures and flavor bans.
Opportunities in the e-vapor category and expansion plans in the U.S.
Strong balance sheet and significant capital returns to shareholders.

Altria reports growth in earnings, navigates regulatory challenges in e-vapor

Altria's Q3 2023 earnings call highlighted solid financial performance, strategic focus on e-vapor products, and efforts to combat illegal vape products. The company faces challenges from regulatory uncertainties and illicit products but sees opportunities in expanding NJOY's reach and addressing market gaps.

Altria reports growth in smoke-free products amidst regulatory challenges

Altria's Q4 2023 earnings call highlighted growth in adjusted EPS, strategic focus on smoke-free products, and efforts to combat illicit e-vapor products. The company faces challenges in competitive segments and economic pressures but sees opportunities in new product introductions and regulatory collaborations.

Altria reports mixed Q1 performance, focuses on growth strategies

Altria's Q1 performance showed growth in NJOY and oral tobacco segments, with challenges in EPS decline and economic pressures on consumers.
Strengths include reaffirmed EPS guidance, strategic investments, and focus on combating illicit e-vapor products.
Opportunities lie in maximizing profitability in oral tobacco, product positioning, and capturing transitioning consumers.
Overall, Altria's performance reflects a mix of growth, challenges, and strategic opportunities in navigating market dynamics.

Altria's NJOY drives growth as company navigates e-vapor challenges

Altria's Q2 2024 earnings call showcased strong performance in smoke-free products, highlighting growth in retail share and volume momentum. Despite challenges in the e-vapor category, the company remains focused on responsible regulation and enforcement. With a commitment to shareholder value and long-term growth strategies, Altria is poised for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Cronos Group

The tobacco giant's $1.8 billion investment isn't going up in smoke. Cronos appears to be using its big cash stockpile wisely.

Why Investors Should Like How Cronos Group Is Spending Altria's Money (So Far)

The tobacco giant looks to cigarette alternatives to build a profitable future.

Altria's Q2 Disappoints, but Sights Are Set on the Future

The tobacco giant’s core business is still withering, but it’s treading water with price hikes, cost-cutting initiatives, and buybacks.

6 Key Takeaways From Altria's Q2 Earnings

Anheuser-Busch InBev

Scotts Miracle-Gro

Constellation Brands

Molson Coors Brewing

These household names are hoping the green rush boosts their bottom lines.

5 Brand-Name Companies Involved in the Marijuana Industry

Altria Group, Inc. (MO) CEO Howard Willard on Q2 2019 Results - Earnings Call Transcript

Cigarette company Altria Group Inc (NYSE: MO) reported second-quarter results that showed mixed trends, according to UBS.

UBS Looks At The Good And Bad From Altria's Q2

Altria (MO) reports in-line earnings in second-quarter 2019. It witnesses impressive top-line performance on robust revenues in the Smokeable Products business.

Altria (MO) Q2 Earnings In Line, Smokeable Unit Aids Sales

Altria Group (NYSE: MO) reported second-quarter earnings of $1.10 per share, which met the analyst consensus estimate.

Altria Group Reports Q2 Earnings Beat

Altria, which sells Marlboro cigarettes, beat Wall Street's revenue expectations but fell short of adjusted earnings expectations. The company expects US cigarette volumes to decline between 5% and 6% this year.

Altria posts mixed quarterly results, says cigarette sales decline is acclerating

Tobacco giant Altria Inc. MO, +0.90% said Tuesday it had net income of $1.996 billion, or $1.07 a share, in the second quarter, up from $1.876 billion, or 99 cents a share, in the year-earlier period.

Altria revenue tops estimates, reaffirms full-year guidance

Altria (NYSE: MO) is set to release its Q2 2019 earnings report on July 30, 2019, followed by a conference call with analysts.

Key Expectations

    Altria Revenues have been decreasing over the last three quarters due to the decline in the sales of cigarettes.

Smokeless Products Expected To Be The Key Driver In Altria's Near Term Revenue And Earnings Growth

Altria Group (NYSE: MO) unveils its next round of earnings this Tuesday, July 30.

Altria Group's Q2 Earnings Outlook

The tobacco giant has diversified to offset a declining cigarette market.

Altria Can Still Overcome Muted Expectations in Q2

The near-term future of CRON stock appears uncertain, but the relationship with Altria could make it succeed as a different type of equity.
The post Cronos Stock Will Benefit From Altria, but Only in the Distant Future appeared first on InvestorPlace.

Cronos Stock Will Benefit From Altria, but Only in the Distant Future

Altria Group (MO) stock is up just 1.5% so far in 2019 to lag behind the tobacco market's nearly 16% climb. Let's see if we should expect this underperformance to continue following the release of Altria's earnings report before the market opens on Tuesday, July 30, or might MO shares get a boost.

What to Expect from Altria Earnings as MO Stock Continues to Struggle

The House Committee on Oversight and Reform's Economic and Consumer Policy subcommittee is examining Juul's marketing and health claims in a two-part hearing on Wednesday and Thursday titled "Examining Juul's Role in the Youth Nicotine Epidemic."

Lawmakers blast Juul over the company's role in teen vaping 'epidemic'

AbbVie

AMC Entertainment

AMTD International Inc

Home Depot

AT&T

Unilever

Welltower

Exxon Mobil

No matter what your investing style, there’s always a place for passive income. Here are nine dividend stocks to buy, ranging from conservative, balanced, and speculative ideas.

9 Dividend Stocks to Buy to Suit Any Investing Style

PepsiCo

Each faces headwinds. Does one look better set for success?

'Better Buy': PepsiCo vs. Altria

Halliburton

Wynn Resorts

There are many sin stocks that are bargains now, but these three stocks to buy stand out from the rest. Here's why.

3 Sin Stocks to Buy That Are Trading at Bargain Prices

Altria's (MO) Q2 performance is likely to gain from RRPs, high pricing and saving initiatives.

Smokeless Unit & Pricing to Boost Altria's (MO) Q2 Earnings

British American Tobacco

Philip Morris

Turning Point Brands

Universal Corp

Vector Group

22nd Century Group

There aren't a huge number of U.S.-listed stocks with a tobacco focus, but these companies still combine to be a force in the global industry.

The 9 Biggest Tobacco Stocks

Disney

Hasbro

Lowe's

McDonald's

Fifty years ago, man landed on the moon and McDonald's and some other stocks took off into the stratosphere. Two of them have more fuel in their jet.

These five stocks are the best performers since man landed on the moon

Colgate-Palmolive

Costco

Estee Lauder

Coca-Cola

Mondelez

Procter & Gamble

Walmart

These companies dominate one of investors' favorite business niches.

The 10 Biggest Consumer Staples Stocks

Just because AT&T, Shell, and Altria have high yields doesn't necessarily make them high risk.

3 Top Dividend Stocks - With Yields Over 5%.

Campaign for Tobacco Free-Kids slammed Juul's "fake apology," saying it's "a blatant attempt to deflect attention from the company's wrongdoing" in "creating the youth e-cigarette epidemic."

News for Altria Stock (MO)